Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health care spending is on people with diabetes.
LocalNews
0
12
Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health care spending is on people with diabetes.
